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ABSTRACT 
 
Background: Canine visceral leishmaniasis (CVL) caused by Leishmania infantum is 
endemic in the northwest and south of Iran. An appropriate vaccine can help to prevent 
and control visceral leishmaniasis in both humans and animals. Few studies have 
confirmed that the fucose-mannose ligand (FML) antigen of Leishmania donovani 
produced protective immunity in dogs against CVL. Objective: To evaluate the 
immune responses of vaccinated dogs against FML antigen of L. infantum. Methods: 
We isolated the FML antigen from native L. infantum and vaccinated the dogs with 
FML-saponin in an endemic area of VL in Iran to evaluate the immune responses of 
vaccinated dogs against this antigen. Results: Our results indicated a significant 
increase in the expression of IFN-γ, IL-10 and IL-13, but not IL-12A, gene transcripts in 
PBMCs of FML-saponin vaccinated dogs in comparison with controls. Our findings 
showed a significant difference in the ratio of IFN-γ/IL-10 mRNA expression in FML-
saponin vaccinated dogs in comparison with two control groups. Moreover, a significant 
level of anti-FML antibodies was detected in serum of vaccinated dogs. Conclusion: 
These findings showed that FML-saponin stimulates both Th1 and Th2 immune 
responses with predominant Th1 and strong humoral immune responses to produce 
protective immunity against CVL. 
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INTRODUCTION 
 
Canine visceral leishmaniasis (CVL) is endemic in the northwest and south of Iran. 
Leishmania infantum is the causative agent of CVL in Iran and the Mediterranean Basin 
(1). Sero-epidemiological surveys reported the prevalence of approximately 14.2% for 
CVL in endemic areas of Iran, however, higher prevalence was reported in molecular 
studies (2,3). Infected dogs are the main reservoirs of parasite, and these animals play 
an important role in persistence of infection in the environment and transmission of 
parasite to humans. Elimination of seropositive infected dogs being recommended as a 
preventive measure in some situations by the WHO, is usually invasive and is not 
acceptable for owners of dogs, especially when the dogs are asymptomatic (4). Thus, a 
suitable vaccine against CVL can help to prevent and control the disease in both humans 
and animals.  
A vast variety of antigens have been used for vaccination of dogs against CVL. Among 
them, fucose-mannose ligand (FML) antigen, isolated from Leishmania donovani 
promastigotes, in association with saponin, as an adjuvant, is one of the most 
appropriate vaccine candidates producing protective immunity in dogs against CVL. 
FML was the first vaccine (Leishmune®) to be licensed against CVL in Brazil (5). 
Leishmune® has been reported to be safe (6), effective (7) and a transmission blocking 
vaccine against CVL (8).  
Recent studies elucidated that Leishmune® increased the level of IFNγ, IL-4, IgG2 and 
number of CD8+ T cells, while it reduced the number of CD4+/CD25+ T cells in 
vaccinated dogs (5,9-11). Thus far, the FML antigen used for vaccination of dogs is L. 
donovani origin, however, few studies on L. chagasi are available. Here, we isolated the 
FML antigen from native L. infantum and vaccinated the dogs in an endemic area of 
CVL in Iran to evaluate the immune responses of vaccinated dogs against the FML 
antigen. 
 
 
MATERIALS AND METHODS  
 
Study Area and Animal Selection. The study was conducted in a CVL endemic area, 
Agh-Bulagh Village, in the south of Meshkin-Shahr city in the northwest of Iran. 
Meshkin-Shahr is the center of Meshkin-shahr County, in Ardabil Province, north-west 
of Iran where CVL and human visceral leishmaniasis (HVL) are endemic (1). Being in 
Alborz Mountain Range and near the high Sabalan Mountain, it enjoys a moderate 
mountainous climate. Sixty ownership dogs (≤2 years old) were selected from the 
village. All animal works were carried out in strict compliance with the approval of the 
Institutional Animal Ethics Committee of the Shiraz University of Medical Sciences, 
following the NIH guidelines for care and use of experimental animals. Consent forms 
were completed by the owners, and peripheral blood samples were collected with and 
without EDTA to obtain buffy coat and sera for PCR and DAT, respectively. From 60 
dogs, 40 dogs, which were negative for Leishmania, by both PCR and DAT, were 
selected for the study.  
Preparation of the FML Antigen. FML antigen of native L. infantum was prepared as 
originally described by Palatnik et al. (12). Briefly, native L. infantum 
(MCAN/IR/07/Moheb-gh) was mass cultivated in BHI medium. The promastigotes, in 
stationary phase, were harvested (washed by saline), and the pellet was mixed with cold 
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distilled water, and centrifuged twice, and the supernatant was collected. Supernatant 
was boiled for 15 min in 100˚C, and centrifuged, and the supernatant was lyophilized 
for size exclusion chromatography by Bio Gel P-10 Gel (Biorad, U.S.A.). FML antigen 
was collected in void volume, and lyophilized and stored at -20˚C until use. Antigenic 
fractions were detected by SDS-page and western blotting. 
Study Design and Vaccination of Dogs. The study was conducted in November 2010 
and in a cold season when the sand flies are not active as vectors. The selected 40 
seronegative and PCR negative dogs were divided into three groups. The first 20 dogs, 
as the test group, received FML+ saponin; the second group, 10 dogs as the control 
group, received saline injection, and the third group, 10 dogs as the second control 
group, received saponin injection alone. The animals in all three groups received three 
subcutaneous injections, every three weeks, on days 0, 21 and 42, respectively. Groin in 
the right leg was selected as injection site. The test group received 1 mL of saline 
containing 1.5 mg of FML and 0.5 mg of saponin in every injection, whereas the saline 
control group received 1 mL of saline alone, and the third group received 1 mL of saline 
containing 0.5 mg of saponin. 
Sample Collection from the Vaccinated Dogs. Ten days after the last injection, totally 
17 mL of peripheral blood sample was taken from each dog. Seven mL in heparin 
contained vacutainer tubes for culturing peripheral blood mononuclear cells (PBMCs). 
Serum samples were collected from 5 mL of clotted peripheral blood of dogs to detect 
anti-FML antibodies by FML-ELISA. To detect possible adventitious infection in 
vaccinated dogs, the remained 5 mL of peripheral blood samples was collected in 
EDTA for PCR assay. 
kDNA Amplification by Nested PCR to Identify Leishmania Infected Dogs. A 
nested PCR was used, as described by Noyes et al. (13) using external primers  
CSB2XF (C/GA/GTA/GCAGAAAC/TCCCGTTCA) and 
CSB1XR (ATTTTTCG/CGA/TTTT/CGCAGAACG), and internal primers 13Z 
(ACTGGGGGTTGGTGTAAAATAG) and LiR (TCGCAGAACGCCCCT), to amplify 
the kDNA of Leishmania on buffy coat samples of all 60 selected dogs and on buffy 
coat of 40 vaccine-inoculated dogs to identify possible adventitious infection in the 
animals.  
Direct Agglutination Test (DAT). DAT was performed to detect anti-Leishmania 
antibodies in the sera of dogs as described by Mohebali et al. (1,3). 
Fucose-Mannose Ligand-ELISA (FML-ELISA). Serum samples from all 40 dogs 
were collected 10 days after the last injection for evaluation of anti-FML antibodies, by 
FML-ELISA. FML-ELISA was performed as described before (14). 
Cultivation of PBMCs from Immunized Dogs. The PBMCs were separated from the 
blood samples of the 40 dogs by Ficoll (Biosera, Korea) based on the manufacturer’s 
instruction. Cells were cultivated in RPMI media (2 × 106 cells/mL) supplemented with 
10% of fetal calf serum (Gibco, U.S.A.) and 1% penicillin-streptomycin 100X (Biosera, 
Korea) in a humidified incubator at 37˚C and 5% CO2 for 12 hours. A four-well culture 
plate was used for each dog (2 mL media containing 4 × 106 cells/well). FML (100 
µg/mL), concanavalin A (Con A) (4 µg/mL) and FML+ Con A were added to three of 
the wells, while one well remained untreated. The ConA co-cultures cells were used as a 
positive control for lymphocyte proliferation and cytokine expression, while FML-
ConA co-cultures were used to evaluate possible effect of ConA on cytokines 
expression. The cells were harvested after 12 hours and washed with phosphate buffered 
saline (PBS) before RNA extraction.  
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RNA Extraction and cDNA Synthesis. Total RNA of cultivated PBMC was extracted 
by TRIzol reagent (Invitrogen, U.S.A.) based on the manufacturer’s instruction. Briefly, 
harvested cells were washed two times with ice cold PBS and resuspend in 100 µL of 
PBS. One mL of TRIzol was added to each tube and incubated on ice for further lysing. 
Then 250 µL of chloroform was added to each tube and samples were centrifuged at 
15000 ×g for 20 min, and RNA in the upper phase was pelleted by absolute isopropanol. 
The RNA pellet was washed by 75% ethanol and eluted in the DEPC-treated water. To 
prevent DNA contamination, 5 µg of total extracted RNA was mixed by 2 units of 
DNase I (Invitrogen-Gibco, Paisley, U.K.) and incubated at 37˚C for 30 min and then at 
65˚C for 10 min to inactivate DNase I. A kit was used for cDNA synthesis (Fermentas, 
Lithuania) and cDNA was prepared based on the manufacturer’s instruction.  Briefly, 5 
µg of total RNA in 10 µL of DEPC treated water and 1 µL of oligo dT and 1 µL of 
Random Hexamer primer were added into 0.5 ml microtubes and incubated for 5 min at 
70˚C in Dri-Block (Techne, U.K.). Then 4 µL of reaction buffer (5 X), 2 µL of dNTP 
(10 mM) and 1 unit of RNase inhibitor were added to each microtube. The microtubes 
were incubated for 5 min at 37˚C followed by 5 min at 25˚C. Then 1 µL of reverse 
transcriptase enzyme (5 units) was added to all microtubes, and samples were incubated 
at 42˚C for 90 min in thermal cycler (Eppendorf, Germany). The samples were 
incubated at 70˚C for 10 min to inactivate the reverse transcriptase enzyme, and the 
prepared cDNA were stored at -70˚C until use. 
Quantitative Real-Time PCR to Evaluate Dog Cytokines Profile after Vaccination 
with FML-Saponin. Quantitative real-time PCR was used to evaluate the expression of 
IL-10, IL-12A, IL-13, IFNγ in vaccinated along with controls dogs. Beta-actin 
housekeeping gene was used as an indicator for other target genes expression levels. 
The primers used  to identify Canis familiaris IL-10, IL-12A, IL-13, IFNγ and beta-
actin gene transcripts were: IL-10 forward, (5-AGGCTGCGACGCTGTCACC-3) and 
reverse, (5-TGCGCTCTTCACCTGCTCCA-3); IL-12A forward, (5-TCACAAAGGAT 
AAAACCAGCACAG-3) and reverse, (5-GCACAGGACCGTCATAAAAGAGG-3); 
IL-13 forward, (5-GCGGCAGGGCAGATTTCC-3) and reverse, (5-AGTGGTCA 
GGTCTGGGTCTAC-3); IFNγ forward, (5-GTGTTCTTCTGGCTGTAACTGTC-3) 
and reverse, (5-TTGTCACTCTCCTCTCTCCATTTC-3); β-actin forward, (5-
TATGTTTAATACCGCCTATTCCAG-3) and reverse, (5-CCTTCCCAACCCTG 
TTAGAC-3). The primers were selected on different exons for each cytokine. Each 
PCR reaction was performed in a final volume of 20 μL containing 0.5 μg of the cDNA 
product, 150 nM of each primer, and 1X reaction mixture consisting of FastStart DNA 
polymerase, dNTPs, reaction buffer and SYBR green I provided by supplier (ABI, 
U.S.A.).  
Thermal cycling to amplify all genes was performed with initial heating to 95°C for 10 
min (denaturation step), followed by 40 cycles of denaturation at 95°C for 15 s, 
annealing at 56°C for 20 s and extension at 60°C for 60 s, respectively. Fluorescence 
acquisition was measured in the final step of each extension step. Accuracy of the 
quantitative real-time PCR amplification was verified by performing melting curve 
analysis after each run. The efficiency of real-time PCR was determined using 
logarithmic dilutions of one of the cDNA samples in reactions with different primer 
pairs, and standard curves were plotted for these samples. The efficiency of reactions 
was calculated by the equation: Efficiency=10 (-1/slope).  
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Statistical Analysis. The levels of IFN-γ, IL-10, IL-12A, and IL-13 gene transcripts 
were evaluated between different groups of dogs using 2–ΔCt method combined with 
Pfaffl model (15). To calculate the target gene expression in each condition, the 
following equation was applied; 
Expression target gene/ACTB (housekeeping gene) =  
(1 + efficiency of target gene) – Ct/(1 + efficiency of ACTB) – Ct 
Upper calculation was executed by Microsoft Excel 2007 software. Gene expression 
difference between groups was revealed by nonparametric Mann-Whitney and 
Spearman correlation nonparametric tests, using SPSS software v. 15.0. In all statistical 
analyses, p<0.05 was considered significant. 
 
 
RESULTS 
 
Antigenic pattern of the FML antigen of native L. infantum.   
Antigenic fractions relevant to glycoprotein antigens were detected by SDS-page and 
western blot (Fig. 1). Western blotting of native L. infantum FML-Ag showed 36 kDa 
band similar to FML-Ag of L. donovani (12). Furthermore, the stronger bands were 
observed in approximately 22 and 25 kDa zones, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Western blot pattern of FML antigen of native L. infantum. 
 
 
 
Detection of anti-FML antibodies in vaccinated dogs. 
FML-ELISA was performed to evaluate anti-FML antibodies in serum samples of 
FML-saponin vaccinated dogs and control groups. Significant level of anti-FML 
~ 10.5 kDa
~ 42 kDa
~ 95 kDa
~ 22 kDa 
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antibodies was detected in the sera of all of the 20 FML-saponin injected dogs, but not 
in the sera of saline or saponin injected control groups (Fig. 2). 
 
 
Figure 2. Levels of anti-FML 
antibodies in vaccinated dogs. Anti-
FML IgG in serum samples of FML-
saponin injected dogs and control 
groups. Rate of antibody in saline 
injected dogs (0.0796 ± 0.006802) 
was equal with saponin injected dogs 
(0.0801 ± 0.008212). Rate of 
produced anti-FML IgG in FML-
saponin injected dogs (0.3596 ± 
0.05627) was significant in 
comparison with control groups 
(p<0.0001). Median of each column 
was showed by solid line. In box plots 
max and min of each column were 
showed by error bar. 75% and 25% 
percentile were showed in box. Data were analyzed by t-test and p value less than 0.05 
considered as statistically significant and represented by (*) as p value less than 0.05 and (**) 
as p value less than 0.01 and (***) as p value less than 0.001 in the graph. 
 
 
IFN-γ mRNA expression.  
Analysis of real-time PCR data showed that IFN-γ mRNA expression was significantly 
up-regulated in FML-saponin injected dogs in comparison to other two groups of 
animals (p<0.0001). Moreover, the levels of expression of IFN-γ were significantly 
elevated in ConA and FML-ConA treated groups in comparison to those in the control 
group (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Levels of IFN-γ mRNA in PBMCs co-culture of vaccinated dogs. Median of each 
column was showed by solid line. In box plots max and min of each column were showed by 
error bar. 75% and 25% percentile were showed in box.  Data were analyzed by Mann Whitney 
t-test and p value less than 0.05 considered as statistically significant and represented by (*) as 
p value less than 0.05 and (**) as p value less than 0.01 and (***) as p value less than 0.001 in 
the graph. 
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IL-10 mRNA expression. 
Expression of IL-10 mRNA was significantly (p=0.0001) elevated in FML-saponin 
vaccinated dogs in comparison with the rest of groups (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Levels of IL-10 mRNA in PBMCs 
co-culture of vaccinated dogs. Median of 
each column was showed by solid line. In box 
plots max and min of each column were 
showed by error bar. 75% and 25% percentile 
were showed in box. Data were analyzed by 
Mann Whitney t-test and p value less than 0.05 
considered as statistically significant and 
represented by (*) as p value less than 0.05 
and (**) as p value less than 0.01 and (***) as p 
value less than 0.001 in the graph. 
 
 
 
 
 
 
 
IL-12A mRNA expression. 
There were no significant differences in expression of IL-12A between FML-saponin 
vaccinated dogs and other groups. However, in saponin and FML-saponin injected dogs, 
the differences in expression of IL-12A were significant in ConA treated and FML-
ConA treated groups compared to the untreated group (Fig. 5). 
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Figure 5. Levels of IL-12A mRNA in PBMCs 
co-culture of vaccinated dogs. Median of 
each column was showed by solid line. In box 
plots max and min of each column were 
showed by error bar. 75% and 25% percentile 
were showed in box. Data were analyzed by 
Mann Whitney t-test and p value less than 0.05 
considered as statistically significant and 
represented by (*) as p value less than 0.05 
and (**) as p value less than 0.01 and (***) as p 
value less than 0.001 in the graph. 
 
 
 
 
IL-13 mRNA expression. 
While the differences in expression of IL-13 in control groups were insignificant, these 
differences in saponin injected (p=0.0379) and FML-saponin vaccinated dogs were 
significant (p<0.0001) (Fig. 6). 
 
 
Figure 6. Levels of IL-13 mRNA in PBMCs co-culture of vaccinated dogs. Median of each 
column was showed by solid line. In box plots max and min of each column were showed by 
error bar. 75% and 25% percentile were showed in box. Data were analyzed by Mann Whitney 
t-test and p value less than 0.05 considered as statistically significant and represented by (*) as 
p value less than 0.05 and (**) as p value less than 0.01 and (***) as p value less than 0.001 in 
the graph. 
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IFN-γ/IL-10 mRNA expression ratio. 
IFN-γ/IL-10 expression ratio was calculated to evaluate Th1/Th2 responses in 
vaccinated dogs. Analysis of results demonstrated a significant difference in ratio of 
IFN-γ/IL-10 expression in FML-saponin vaccinated dogs (p=0.0275), while such 
differences were not found in saline and saponin injected dogs (Fig. 7). 
 
 
Figure 7. IFN-γ/IL-10 expression 
ratio in PBMCs co-culture of 
vaccinated dogs. Median of each 
column was showed by solid line. In 
box plots max and min of each 
column were showed by error bar. 
75% and 25% percentile were 
showed in box. Data were analyzed 
by Mann Whitney t-test and p value 
less than 0.05 considered as 
statistically significant and 
represented by (*) as p value less 
than 0.05 in the graph. 
 
 
 
 
 
DISCUSSION 
 
Many vaccine candidate antigens have been evaluated for vaccination of dogs against 
canine visceral leishmaniasis. Among these, satisfactory results have been reported for 
FML-saponin in phase III trials, and a vaccine against CVL (Leishmune®) has been 
licensed and is commercially available in Brazil (16). In the current study, we prepared 
the FML antigen from native L. infantum in Iran and vaccinated the dogs in an endemic 
area of CVL to evaluate the immune responses of vaccinated dogs against the FML 
antigen. 
Our results demonstrated a significant increase in expression of IFNγ, IL-10 and IL-13 
gene transcripts in PBMCs co-cultured from FML-saponin injected dogs in comparison 
to control group. However, such differences were not seen in expression of IL-12A. We 
also found a significant difference in ratio of IFN-γ/IL-10 mRNA expression in FML-
saponin injected dogs in comparison with control group. Levels of expression of IFN-γ 
and IL-4 in dogs after vaccination with FML antigen have been evaluated in few 
studies. Araujo et al. (10) demonstrated mixed Th1/Th2 responses to Leishmune® in 
PBMC culture of vaccinated dogs with increase in IL-4+ T-cells and predominant 
increase in IFN-γ+ T-cells. Significant increase in the IFN-γ+/IL-4+ T-cells ratio 
verified a Th1 response in vaccinated dogs in their study. These findings are in 
concordance with our results. Increased level of IFN-γ in Leishmune® vaccinated dogs 
was also reported by de Lima et al. (11).  
Our results showed a general up-regulation of anti-FML immune responses in 
vaccinated dogs with predominant Th1 immune responses. Many studies have been 
conducted on symptomatic and asymptomatic dogs as well as vaccinated dogs to 
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explore the role of Th1 and Th2 responses in developing immunity to CVL. Results of 
such studies confirmed that Th1 mediated immune responses contributed to resistance, 
and Th2 mediated immune responses contributed to susceptibility to infection. 
However, co-existence of mixed Th1/Th2 immune responses against Leishmania 
infections in symptomatic and asymptomatic animals has been reported in quite a few 
studies (17,18). In one study on cytokine profile in spleen cells of dogs naturally 
infected by L. chagasi, Lage et al. demonstrated an increased level of both Th1 and Th2 
immune responses in both symptomatic and resistant asymptomatic dogs with 
differences in proportion of produced related cytokines (19).  
Evaluation of immune responses in asymptomatic dogs, as an animal model with 
immune competent and resistant to clinical disease, can be useful. In one study on 
cytokine expression levels in asymptomatic naturally infected dogs by Manna et al. 
(18), high level of IFN-γ, IL-2 and IL-18 cytokines expression at the beginning of 
infection, and appearance of IL-4 and IL-10 cytokines in addition to IFN-γ, IL-2 and IL-
18, six month later, was confirmed. IL-12 was the only undetected cytokine in 
asymptomatic dogs at the beginning, 6 and 24 months after infection in animals. In the 
same study, six months after infection, high levels of IL-2, IL-4 and IL-10 and low level 
of IFN-γ were found in symptomatic dogs. Interestingly, significant level of IL-12 was 
found only in symptomatic dogs six months after infection, representing IL-12 as a 
marker of active disease (18).  
In our study, contrary to our expectation, the level of IL-12A mRNA expression in 
vaccinated dogs was not significant. IL-12 has a heterodimer structure, combined of a 
light chain (known as p35 or IL-12α) and a heavy chain (known as p40 or IL-12β) that 
encoding by separate genes (20,21). Recent studies demonstrated that expression of the 
IL-12 p35 controls IL-12 production (22,23). Babik et al. (24) showed that the p35 gene 
was highly regulated and controlled in translation and transcription. Accordingly, higher 
level of IL-12 in vaccinated dogs might have been seen in our study if we measured the 
IL-12 in secreted protein form. Our results showed a significant increase in the 
expression of IL-10 mRNA in vaccinated dogs. Direct correlation has been found 
between the increased level of IL-10, clinical signs and high parasite load in CVL (19). 
Contrary to these findings, Quinnell et al. (25) showed that the level of IL-10 and IL-13 
in infected dogs was not significant and suggested that IL-10 might not play an 
immunosuppressive role in dogs as it does in the human VL.  
The Leishmune® vaccine causes an increase in CD8+ total lymphocytes population in 
the blood (9,26) and a decrease in CD4+/CD25+ T cells in vaccinated dogs (11). These 
cells might be the source of IL-10 in our study. We have detected a significant level of 
IL-13 in vaccinated dogs in our study. Sanchez-Robert et al. (27) maintain that absence 
of IL-4 and IL-13 in the first stage of Leishmania infection in asymptomatic dogs can 
create protection against replication of parasite. Our results are inconsistent with the 
study of Quinnell et al. showing no enhancement in IL-13 in infected dogs (25). 
Considering the protective effect of FML-saponin vaccine and the results of our study 
as well as in view of the above-mentioned studies, increased levels of IL-10 and IL-13 
in vaccinated dogs could not be solely considered an immunosuppressive response. Our 
findings demonstrated a significant level of anti-FML antibodies in serum of vaccinated 
dogs. This in turn shows a strong humoral response to FML antigen in FML-saponin 
vaccinated dogs. This finding is in line with findings reported in other studies (7,11,28). 
Bourdoiseau et al. (29) reported enhanced level of IgG2 anti-Leishmania excretory-
secretory antigen (anti-LiESAp) in serum of vaccinated dogs, and showed that vaccine-
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induced antibody in serum of vaccinated dogs reduced capacity of promastigotes to 
infect canine macrophages in vitro and had an inhibitory effect on the viability and 
proliferation of parasites.In our study, the level of total IgG was measured in vaccinated 
dogs, while subclass of IgG might be important in immune responses of dogs against 
the vaccinated antigen. Increased IgG2 anti-FML antibody has been detected in dogs 
vaccinated with FML-vaccine (10,30), while enhanced total IgG along with enhanced 
IgG1 was detected in serum of dogs with active CVL (30). 
In conclusion, FML-saponin stimulates Th1 and Th2 associated with predominant Th1 
immune responses as well as strong humoral immune responses to produce protective 
responses against CVL. Considering the diversity of cytokines functions in various 
conditions and in different animal models, further studies on natural reservoirs of VL 
are needed to explore the details of immune responses induced by the FML-saponin 
vaccine. 
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